Geron to Announce Second Quarter 2021 Financial Results on August 16, 2021

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) will release its Q2 2021 financial results after market close on August 16, 2021. The results will be detailed in a press release available on the company’s website. Following this, a conference call will be held at 4:30 p.m. ET to discuss the results and recent events. Key highlights include ongoing Phase 3 clinical trials for imetelstat in hematologic malignancies. A live webcast will also be accessible on the company's site, with an archive available for 30 days.

Positive

• Conducting two Phase 3 clinical trials: IMerge and IMpactMF.
• Focused on the development of a first-in-class telomerase inhibitor, imetelstat.

Negative

• None.

Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter and year to date 2021 financial results after the market closes on Monday, August 16, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day.

A live, listen-only webcast will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the conference call live via telephone by pre-registering online using the following link, http://www.directeventreg.com/registration/event/5548255. Upon registration, a phone number, Direct Event Passcode and unique Registrant ID will be sent via email. This information will be needed in order to enter the conference call. Participants are advised to pre-register at least 10 minutes prior to joining the call.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005933/en/

FAQ

What is the date for Geron's Q2 2021 financial results release?

Geron's Q2 2021 financial results will be released on August 16, 2021.

When will Geron hold its conference call to discuss financial results?

The conference call will be held at 4:30 p.m. ET on August 16, 2021.

What clinical trials is Geron currently conducting?

Geron is conducting two Phase 3 clinical trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

Where can I find Geron's financial results and webcast?

Geron's financial results will be available on their website, and a live webcast will also be hosted there.